lixisenatide + biguanide

Combination of **lixisenatide**, a short-acting glucagon-like peptide-1 (GLP-1) receptor agonist, and a **biguanide**, typically referring to metformin, used in the management of type 2 diabetes mellitus. Lixisenatide acts as an incretin mimetic, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, and slowing gastric emptying. Biguanides such as metformin primarily reduce hepatic glucose production and improve insulin sensitivity. The combination is used to improve glycemic control in adults with type 2 diabetes inadequately controlled on oral antidiabetic agents or insulin, with additive effects on lowering blood glucose and potential for weight loss or weight neutrality.